Cytodyn Inc (CYDY)

[Bill_ENG]

Some cannot separate the fact that Leronlimab did not fail at anything.

What the trial data shows is that in the 62 patients which were the worst the placebo plus standard of care could not match LL's benefit.

In the other severe category which had more subjects the Placebo plus SOC still did not perform as well as Leronlimab but performed well enough to deny LL the P-Value.

In all categories LL beat the SOC alone. It just did not beat SOC by a large enough margin